As of 2025-09-16, the Relative Valuation of Ultragenyx Pharmaceutical Inc (RARE) is (109.63) USD. This relative valuation is based on P/E multiples. With the latest stock price at 29.00 USD, the upside of Ultragenyx Pharmaceutical Inc based on Relative Valuation is -478.0%.
The range of the Relative Valuation is (92.68) - (113.81) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.4x - 20.6x | 18.0x |
| Forward P/E multiples | 16.8x - 26.5x | 21.6x |
| Fair Price | (92.68) - (113.81) | (109.63) |
| Upside | -419.6% - -492.4% | -478.0% |
| Date | P/E |
| 2025-09-15 | -5.24 |
| 2025-09-12 | -5.48 |
| 2025-09-11 | -5.65 |
| 2025-09-10 | -5.66 |
| 2025-09-09 | -5.70 |
| 2025-09-08 | -5.70 |
| 2025-09-05 | -5.75 |
| 2025-09-04 | -5.66 |
| 2025-09-03 | -5.71 |
| 2025-09-02 | -5.79 |
| 2025-08-29 | -5.42 |
| 2025-08-28 | -5.48 |
| 2025-08-27 | -5.44 |
| 2025-08-26 | -5.35 |
| 2025-08-25 | -5.29 |
| 2025-08-22 | -5.39 |
| 2025-08-21 | -5.34 |
| 2025-08-20 | -5.31 |
| 2025-08-19 | -5.27 |
| 2025-08-18 | -5.37 |
| 2025-08-15 | -5.37 |
| 2025-08-14 | -5.25 |
| 2025-08-13 | -5.24 |
| 2025-08-12 | -5.08 |
| 2025-08-11 | -4.95 |
| 2025-08-08 | -4.98 |
| 2025-08-07 | -5.03 |
| 2025-08-06 | -5.07 |
| 2025-08-05 | -5.23 |
| 2025-08-04 | -5.15 |
| 2025-08-01 | -5.14 |
| 2025-07-31 | -4.94 |
| 2025-07-30 | -4.91 |
| 2025-07-29 | -5.00 |
| 2025-07-28 | -4.99 |
| 2025-07-25 | -4.94 |
| 2025-07-24 | -4.94 |
| 2025-07-23 | -5.07 |
| 2025-07-22 | -4.78 |
| 2025-07-21 | -4.77 |
| 2025-07-18 | -4.76 |
| 2025-07-17 | -4.96 |
| 2025-07-16 | -4.94 |
| 2025-07-15 | -4.92 |
| 2025-07-14 | -5.29 |
| 2025-07-11 | -5.34 |
| 2025-07-10 | -5.61 |
| 2025-07-09 | -7.49 |
| 2025-07-08 | -7.13 |
| 2025-07-07 | -7.16 |